Articles published by Xencor, Inc.
Xencor Reports Third Quarter 2024 Financial Results
November 06, 2024
From Xencor, Inc.
Via Business Wire
Tickers
XNCR
Xencor Doses First Subject in Phase 1/2 Study of XmAb®942 in Development for Patients with Inflammatory Bowel Disease
November 04, 2024
From Xencor, Inc.
Via Business Wire
Tickers
XNCR
Xencor Announces Upcoming Change to Board of Directors
October 04, 2024
From Xencor, Inc.
Via Business Wire
Tickers
XNCR
Xencor Announces Closing of Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
September 12, 2024
From Xencor, Inc.
Via Business Wire
Tickers
XNCR
Xencor Announces Pricing of $175 Million Public Offering of Common Stock
September 11, 2024
From Xencor, Inc.
Via Business Wire
Tickers
XNCR
Xencor Announces Proposed Public Offering of Common Stock
September 10, 2024
From Xencor, Inc.
Via Business Wire
Tickers
XNCR
Xencor to Host Research & Development Webcast and Conference Call on Monday, September 9, 2024
September 06, 2024
From Xencor, Inc.
Via Business Wire
Tickers
XNCR
Xencor Reports Second Quarter 2024 Financial Results
August 05, 2024
From Xencor, Inc.
Via Business Wire
Tickers
XNCR
Xencor Regains CD20 x CD3 Bispecific T-Cell Engager
June 13, 2024
From Xencor, Inc.
Via Business Wire
Tickers
XNCR
Xencor Reports First Quarter 2024 Financial Results
May 09, 2024
From Xencor, Inc.
Via Business Wire
Tickers
XNCR
Xencor Appoints Bart Cornelissen as Chief Financial Officer
April 09, 2024
From Xencor, Inc.
Via Business Wire
Tickers
XNCR
Xencor to Present at Upcoming Investor Conferences
February 28, 2024
From Xencor, Inc.
Via Business Wire
Tickers
XNCR
Xencor Reports Fourth Quarter and Full Year 2023 Financial Results
February 27, 2024
From Xencor, Inc.
Via Business Wire
Tickers
XNCR
Xencor to Host Webcast to Review Fourth Quarter and Full Year 2023 Financial Results and Provide Vudalimab Clinical Update
February 20, 2024
From Xencor, Inc.
Via Business Wire
Tickers
XNCR
Dane Leone Joins Xencor as Senior Vice President, Corporate Strategy
January 02, 2024
From Xencor, Inc.
Via Business Wire
Tickers
XNCR
Xencor Reports Third Quarter 2023 Financial Results
November 07, 2023
From Xencor, Inc.
Via Business Wire
Tickers
XNCR
Xencor Sells Portion of Royalties and Milestones from Ultomiris® and Monjuvi® to OMERS Life Sciences for $215 Million
November 07, 2023
From Xencor, Inc.
Via Business Wire
Tickers
XNCR
Xencor Presents Preclinical Data from Multiple XmAb® Research Programs at the SITC Annual Meeting
November 03, 2023
From Xencor, Inc.
Via Business Wire
Tickers
XNCR
Xencor to Host Third Quarter 2023 Financial Results Webcast and Conference Call on November 7, 2023
October 31, 2023
From Xencor, Inc.
Via Business Wire
Tickers
XNCR
Xencor to Present Multiple Posters at the SITC Annual Meeting
September 27, 2023
From Xencor, Inc.
Via Business Wire
Tickers
XNCR
Xencor Appoints Barbara J. Klencke, M.D., to Board of Directors
September 19, 2023
From Xencor, Inc.
Via Business Wire
Tickers
XNCR
Xencor Reports Second Quarter 2023 Financial Results
August 03, 2023
From Xencor, Inc.
Via Business Wire
Tickers
XNCR
Xencor to Host Second Quarter 2023 Financial Results Webcast and Conference Call on August 3, 2023
July 27, 2023
From Xencor, Inc.
Via Business Wire
Tickers
XNCR
Xencor Presents Clinical Results from Phase 1a Study of XmAb®564 at the EULAR 2023 Congress
May 30, 2023
From Xencor, Inc.
Via Business Wire
Tickers
XNCR
Xencor Reports First Quarter 2023 Financial Results
May 08, 2023
From Xencor, Inc.
Via Business Wire
Tickers
XNCR
Xencor to Host First Quarter 2023 Financial Results Webcast and Conference Call on May 8, 2023
May 01, 2023
From Xencor, Inc.
Via Business Wire
Tickers
XNCR
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.